EHRA Premium Access

A real-world comparison of vernakalant efficacy and safety for pharmacological cardioversion in patients with recent-onset atrial fibrillation in an emergency department and after cardiac surgery.

Congress Session

About the speaker

Doctor Joaquin Osca Asensi

Hospital La Fe, Valencia (Spain)
2 presentations
0 follower

6 more presentations in this session

Vernakalant versus ibutilide for immediate conversion of recent-onset Atrial Fibrillation

Speaker: Doctor I. Vogiatzis (Veria, GR)

Thumbnail

Intravenous antazoline for cardioversion of recent onset atrial fibrillation in patients with stable coronary artery disease.

Speaker: Doctor M. Farkowski (Warsaw, PL)

Thumbnail

Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study

Thumbnail

Comparison of local activation time annotation algorithms in high density mapping of regular atrial tachycardias

Speaker: Professor J. De Pooter (Ghent, BE)

Thumbnail

Higher persistence but lower compliance with direct oral anticoagulants treatment for atrial fibrillation following a personalized therapeutic information: paradoxical results of the MONACO study

Speaker: Professor J. Davy (Montpellier, FR)

Thumbnail

Access the full session

Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

Speakers: Doctor J. Osca Asensi, Doctor I. Vogiatzis, Doctor M. Farkowski, Professor J. De Pooter, Professor J. Davy
Thumbnail

About the event

Image

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk